PeptideApprove vs AllayPay

AllayPay is a generalist high-risk processor that onboards peptide merchants among many other categories. PeptideApprove is built only for peptide brands. Here is what that difference means in practice.

§ Verdict

Pick PeptideApprove if you want pricing confirmed in writing after underwriting, faster sponsor-bank review, and payout flexibility. Pick AllayPay if you want cross-category coverage and don't mind quote-only pricing.

Feature-by-feature

Side-by-side comparison.

Feature	PeptideApprove	AllayPay
Industry rate range	pricing confirmed after underwriting	5–15%
Serves RUO + Healthcare	✓ Both tracks — RUO label-compliance path or LegitScript-certified pharmacy path	Unclear / case-by-case
Pricing model	Confirmed after underwriting	Quote-only, case-by-case
Reserve schedule	Confirmed in the merchant agreement.	Quote-only, typically 180 days
LegitScript for compliant RUO retailers	✓ Not required	— Pass-through
Peptide-specific underwriting	✓ Peptide-only by design	— Generalist high-risk
Onboards MATCH-listed merchants	Yes, with documented cause + LegitScript	Yes (broad)
Onboarding (compliant merchant)	48-hour underwriting response	"Quick" (claimed)
Application fee	$0	Varies
Won't onboard guarantee	If we can't lower your TCO, we won't onboard you	—

The honest assessment

Where each one actually wins.

PeptideApprove wins on:

Pricing transparency. Pricing is confirmed in writing after underwriting, before you sign.
Purpose-built KYB. PeptideApprove reviews peptide merchants against the products, claims, and documents this category actually raises. AllayPay underwrites across many high-risk categories.
Peptide-specific underwriting. We onboard only peptide brands and configure every account around BRAM. AllayPay is a generalist high-risk processor — their underwriting screen has to accommodate dozens of categories.
LegitScript. Not required for compliant research-use-only retailers. Clinical, pharmacy, and telehealth models are reviewed on a separate path.
Onboarding speed. 48-hour underwriting response for eligible merchants with complete information, versus a multi-week industry review.

AllayPay wins on:

Cross-category coverage. AllayPay onboards CBD, nutraceuticals, supplements, and several other high-risk categories. If your portfolio spans categories beyond peptides, AllayPay's breadth is useful.
Established brand. AllayPay has been in the high-risk space for years. If brand age is your decision criterion, that history matters.
Phone-first sales. AllayPay takes inbound sales calls before quoting. PeptideApprove is web + email until you've seen your number.

Decision guide

Which one should you actually pick?

If you sell only peptides

PeptideApprove. Peptide-specific underwriting and pricing transparency outweigh AllayPay's breadth.

If you sell peptides plus CBD or supplements

AllayPay. We don't onboard CBD. AllayPay's cross-category model is the better fit.

If you're on the MATCH list

Either will onboard you. PeptideApprove requires documented cause + a LegitScript path. AllayPay is broader.

If working capital efficiency matters

PeptideApprove. Our 90-day published reserve releases capital roughly 2× faster than the 180-day industry default.

Send us your current statement. We'll show you what you'd save.

Side-by-side analysis in your inbox within 24 hours. No phone calls. No application fee. If we can't lower your total cost of ownership in year one, we won't onboard you.

Apply now → Apply now